Three Novel Therapies Target Frail HNSCC Patients Unable to Tolerate Standard Treatment
Key Insights
Head and neck squamous cell carcinoma cases are projected to increase from 229,000 to 273,000 across eight major markets by 2034, with frail and elderly patients representing 44% of cases.
Three emerging therapies—JNJ-1900, Akalux, and Steboronine (search)—offer new treatment options for patients who cannot tolerate intensive surgery, radiation, and platinum-based chemotherapy.
JNJ-1900 is positioned for broadest global impact with projected sales of $108 million by 2034, while Akalux targets $77.6 million in sales across the same timeframe.
Head and neck squamous cell carcinoma (HNSCC) cases are projected to climb from 229,000 in 2024 to 273,000 by 2034 across eight major markets, driven by tobacco use, areca nut chewing, alcohol consumption, and human papillomavirus. This growing patient population faces significant treatment challenges, particularly among frail and elderly patients who represent nearly 40% of current cases and are expected to reach 44% by 2034.
Standard-of-care regimens with curative intent typically demand intensive surgery, prolonged radiation, and full-dose platinum-based chemotherapy—treatments that many patients cannot tolerate. Even in early-stage disease where cure rates reach 70%-90%, a meaningful subset of patients still relapse, often locoregionally, requiring multimodal management that can compromise quality of life and cause permanent loss of speech, hearing, or swallowing function.
Novel Radioenhancer Technology Shows Promise
Johnson & Johnson's JNJ-1900 (formerly NBTXR3) represents a potentially first-in-class radioenhancer composed of functionalised hafnium oxide nanoparticles. The treatment is delivered through a single intratumoral injection and activated by radiotherapy. The pivotal NANORAY-312 Phase III trial targets platinum-ineligible patients aged 65 years or older with locally advanced HNSCC receiving definitive radiotherapy with or without cetuximab.
The FDA granted JNJ-1900 fast track designation in 2020, and the programme spans multiple other solid tumours. Key opinion leaders emphasized the therapeutic rationale, stating: "Our primary goal is to enhance the effectiveness of radiotherapy in the locally advanced setting…We must continue to explore these specific compounds, as they appear to enhance the potential for curing locally advanced tumours."
Photoimmunotherapy Advances in Japan
Rakuten Medical (search)'s Akalux (cetuximab sarotalocan) is an epidermal growth factor receptor-targeted photoimmunotherapy agent approved in Japan's Conditional Early Approval System in 2020 for unresectable locally advanced or locally recurrent HNSCC. This drug-device combination uses a light-activated antibody-dye conjugate in combination with laser beam irradiation, spanning one to four treatment sessions.
Akalux is reported to have limited effects on surrounding normal tissues, thereby preserving organ functions. Two global Phase III trials are currently underway in patients with locally recurrent HNSCC without distant metastasis—one combining the therapy with MSD's Keytruda (pembrolizumab) in the first-line setting and another as monotherapy in later lines.
Boron Neutron Capture Therapy Enters Market
Steboronine (search) (borofalan¹⁰B), developed by Stella Pharma Corporation, represents a boron neutron capture therapy (BNCT) approach. The treatment was approved in Japan in 2020 based on a Japanese, open-label, uncontrolled trial (Study 002) for unresectable locally advanced or recurrent HNSCC. Treatment involves a single intravenous dose of Steboronine followed by neutron beam irradiation.
Market Positioning and Commercial Outlook
The clinical development landscape for frail HNSCC patients remains nascent, but the substantial unmet need presents significant commercial opportunity. While head-to-head data is not yet available, NBTXR3 appears best-positioned for broad global impact as it requires no specialist laser or neutron accelerator, relying instead on existing radiotherapy infrastructure. GlobalData forecasts NBTXR3 will reach sales of $108 million in HNSCC across the eight major markets by 2034.
Akalux represents a genuinely innovative modality, with Rakuten Medical (search) demonstrating commitment through a $100 million Series F funding round that closed in January 2026, oversubscribed and doubled its initial target to support global Phase III trials. GlobalData projects Akalux will achieve sales of $77.6 million in HNSCC across the eight major markets by 2034.
Steboronine (search)'s global reach will remain constrained by neutron accelerator infrastructure requirements for the foreseeable future, with GlobalData forecasting Japan-only sales of less than $1 million by 2034. The question is no longer whether this population will be treated differently, but which agents will define new treatment standards in which markets.